65岁西班牙人成为赛诺菲史上首位女CEO，为何股价下跌

Core Viewpoint - Sanofi has appointed Belén Garijo as its new CEO, marking the first time a woman has held this position in the company's history. The announcement led to a 4.5% drop in Sanofi's stock price, indicating market skepticism about the leadership change [1][3]. Group 1: Leadership Change - Paul Hudson's tenure as CEO will not be extended, and Belén Garijo, currently the CEO of Merck, will take over on April 29, 2026 [1]. - Garijo has extensive experience, having worked at Sanofi for 15 years prior to her role at Merck, where she faced challenges in new drug development [3]. Group 2: Market Reaction - The market's negative reaction to Garijo's appointment suggests that investors were expecting a more aggressive leader to drive innovation and growth [3]. - Sanofi's stock has declined over 25% in the past year, attributed to stagnation in its drug development pipeline and external pressures such as U.S. vaccine policies [3][4]. Group 3: Challenges Ahead - Garijo will face significant pressure from investors to enhance the company's drug development productivity, which has been a major challenge for Sanofi [3]. - The company is at risk of losing revenue from its key drug Dupixent, which contributes over 30% to its income and will face patent expiration in about five years, with no substantial replacement identified [3]. Group 4: Vaccine Business - Vaccines represent nearly one-fifth of Sanofi's revenue, but sales are under pressure due to a more adversarial stance from U.S. health authorities [4]. Group 5: Transitional Role - Some investors view Garijo's appointment as a transitional role, emphasizing her operational experience over scientific expertise, which may help maintain profitability under pressure [5].